Media headlines about Cytori Therapeutics (NASDAQ:CYTX) have been trending positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cytori Therapeutics earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.1983102820674 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
Several equities research analysts have commented on CYTX shares. Maxim Group set a $5.00 price objective on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Friday, January 5th. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. B. Riley reiterated a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th. Finally, ValuEngine upgraded shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
Cytori Therapeutics (NASDAQ CYTX) traded down $0.01 during trading hours on Monday, reaching $0.32. 1,402,000 shares of the company’s stock traded hands, compared to its average volume of 2,312,318. Cytori Therapeutics has a 52-week low of $0.22 and a 52-week high of $2.08. The stock has a market cap of $11.34, a price-to-earnings ratio of -0.36 and a beta of 3.11.
In other news, major shareholder Ag Postfinance sold 286,982 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $0.31, for a total transaction of $88,964.42. Following the completion of the transaction, the insider now directly owns 5,118,627 shares of the company’s stock, valued at approximately $1,586,774.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the transaction, the insider now directly owns 5,496,655 shares of the company’s stock, valued at $2,088,728.90. The disclosure for this sale can be found here. Insiders have sold a total of 695,767 shares of company stock valued at $231,951 over the last three months. Insiders own 1.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Favorable News Coverage Somewhat Unlikely to Affect Cytori Therapeutics (CYTX) Stock Price” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/19/favorable-news-coverage-somewhat-unlikely-to-affect-cytori-therapeutics-cytx-stock-price.html.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.